As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis

Launched by MAHIDOL UNIVERSITY · Mar 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how effective intranasal corticosteroids (a type of nasal spray) are in treating perennial allergic rhinitis (a long-term allergy condition) in children. The researchers want to compare two different ways of using this medication: one group will use it every day, while the other group will use it only when their symptoms are bothering them. The goal is to find out which method helps children feel better while also reducing the side effects that can sometimes come from using the spray regularly.

To participate in the trial, children aged 6 to 18 who have been diagnosed with moderate to severe allergic rhinitis and have specific allergy test results may be eligible. However, children with certain conditions, like asthma that isn't controlled or other serious health issues, would not be able to take part. Participants will be monitored to see how well each method of treatment works and how it affects their daily lives. This study aims to improve the quality of life for children with allergies while ensuring they have safe and effective treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children patient (age 6 - 18 yr)
• • Mild persistent, Moderate to severe intermittent and persistent perennial allergic rhinitis
• • Rhinitis proven sensitization to aeroallergen by positive skin prick test or specific IgE result within 12 month before study recruitment
• • Mean TNSS = 4 during 7 day duration before randomization (after a washout period, discontinuation of the medications listed in exclusion criteria
• Exclusion Criteria:
• • Patients with rhinosinusitis, nasal polyps, or significant deviated nasal septum
• • Patients with a history of uncontrolled asthma, chronic lung disease, cardiovascular, hepatic, or renal diseases
• • Patients taking oral or nasal decongestants within 7 d
• • Patients taking INCS within 4 week
• • Patients taking systemic corticosteroid within 8 week
• • Patients taking H1 antihistamine within 1 week
• • Patients taking antileukotriene within 4 week
• • Patients who were currently or previously treated with allergen immunotherapy
• • Patients with a history of upper respiratory tract infection within 14 d
• • Patients with primary and secondary immune deficiency